Promising phase 1 data presented by UCI Health radiologist at ASCO 2026
-
June 22, 2026
Clinical Report: Promising Phase 1 Data on Novel Therapy for Pancreatic Cancer
Overview
UCI Health radiologist Dr. Nadine Abi-Jaoudeh presented Phase 1 data at ASCO 2026 on a novel interventional approach for locally advanced pancreatic cancer. This method combines photodynamic therapy with intravascular laser activation.
Background
Locally advanced pancreatic cancer (LAPC) is often deemed unresectable due to tumor encasement of major vessels, leading to poor survival outcomes. Current treatment options primarily involve systemic therapies, with limited success in converting patients to surgical candidates. Innovative approaches are essential to improve survival rates in this challenging patient population.
Data Highlights
No numerical data or trial results were provided in the source material.
Key Findings
- Dr. Abi-Jaoudeh's study targets the 35% of LAPC patients with tumors encasing major vessels.
- The novel approach combines parallel photodynamic therapy with intravascular laser activation via a balloon catheter.
- This technique successfully destroys perivascular tumor tissue.
Clinical Implications
The findings suggest a potential shift in treatment paradigms for LAPC, offering a new avenue for patients who have limited options. Further studies are needed to validate these results and assess long-term outcomes.
Conclusion
The Phase 1 data presented by UCI Health highlights a new interventional strategy for LAPC.
Related Resources & Content
- UCI Health, UCI Health News, 2026 -- UCI Health is at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
- The ASCO Post, ASCO Post, 2025 -- LuPSMA-617 Plus Hormone Therapy Improves Radiographic Progression–Free Survival in Metastatic Hormone-Naive Prostate Cancer
- The ASCO Post, ASCO Post, 2026 -- TAP Homepage - The ASCO Post
- National Cancer Institute, NCI, 2025 -- Pancreatic Cancer Treatment (PDQ®)
- The ASCO Post — Neoadjuvant Immunotherapy May Benefit Patients With Early-Stage NSCLC
- Pancreatic Cancer Treatment (PDQ®) - NCI
- Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study | Journal of Clinical Oncology
- EUS-guided verteporfin photodynamic therapy for pancreatic cancer - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
